Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prasco Laboratories has entered into a distribution and supply agreement with Takeda Pharmaceuticals USA (TPUSA) for the distribution rights of Colchicine Tablets, USP, the Authorized Generic (AG) version of Colcrys (colchicine, USP) Tablets in the US.
Subscribe to our email newsletter
Under the deal, Colchicine Tablets, USP will be the only colchicine product on the market that is therapeutically equivalent and automatically substitutable for prescriptions written for Colcrys Tablets.
Colcrys is indicated for the prophylaxis and treatment of acute gout flares in adults as well as to treat familial Mediterranean fever (FMF) in adults and children aged four years or older.
Beginning later this week, Colchicine Tablets, USP that will be marketed under the Prasco label will be widely available in US pharmacies.
Prasco chief executive officer Chris Arington said: "Introducing an Authorized Generic of Colcrys provides patients, pharmacists, and physicians with access to a therapeutically equivalent option to Colcrys Tablets for the prevention and treatment of gout flares."
Colcrys is approved by the US Food and Drug Administration (FDA) as a single-ingredient oral colchicine product and it is now available in the US with prescription.